

CONTACT
040 6761 1600 / 6761 1700
neuland@neulandlabs.com
neulandlabs.com

May 15, 2025

To
BSE Limited
Phiroze Jeejeebhoy Towers, 25th Floor, Dalal
Street, Mumbai – 400 001

The National Stock Exchange of India Ltd
Exchange Plaza,
Bandra Kurla Complex
Bandra (E), Mumbai – 400 001

Scrip Code: 524558

Scrip Code: NEULANLAB; Series: EQ

Dear Sir/Madam,

Sub: Outcome of Board Meeting

Pursuant to Regulation 30 and 33 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations"), we wish to inform you that the Board of Directors at their meeting held on even date, have considered and approved the following:

A. Financial Results

Upon recommendation of the Audit Committee, the Board of Directors have approved the Audited Financial Results (Standalone & Consolidated) as per Indian Accounting Standards (IND AS) for the year ended March 31, 2025 along with Statement of Assets and Liabilities as on March 31, 2025 (enclosed). The Board of Directors took note of the Statutory Auditors' Report on the Audited Financial Results (Standalone & Consolidated) for the year ended March 31, 2025 with unmodified opinion (enclosed).

We would like to state that the Statutory Auditors of the Company, M/s. MSKA & Associates, Chartered Accountants, have issued audit reports with unmodified opinion on the financial statements.

B. Final Dividend

Recommended payment of final dividend of Rs. 12/- (120 %) per equity share on a face value of Rs.10 each, for the financial year 2024-25. The dividend will be paid on or after five days from the date of declaration of the final dividend by the shareholders at the 41st Annual General Meeting (AGM).

C. Re-appointment of Mr. Davuluri Saharsh Rao (DIN: 02753145), as Whole Time Director, designated as Vice Chairman & Managing Director

Re-appointment of Mr. Davuluri Saharsh Rao (DIN: 02753145), as Whole Time Director, designated as Vice Chairman & Managing Director, for a further period of 5 (five) years, w.e.f. June 1, 2025, basis the recommendation of the Nomination and Remuneration Committee, subject to the approval of the shareholders of the Company in the ensuing AGM.

The details as required under Regulation 30 of the SEBI Listing Regulations, read with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, with respect to the above re-appointment is enclosed as **Annexure A**.



D. Annual General Meeting (AGM) and Record Date

Approved convening of 41st AGM of the shareholders of the Company on Wednesday, July 30, 2025.

Pursuant to Regulation 42 of SEBI Listing Regulations the record date for the purpose of determining the shareholders eligible to receive the final dividend for the financial year ended March 31, 2025, has been fixed as July 18, 2025.

E. Appointment of Secretarial Auditors

Upon recommendation of the Audit Committee, the Board of Directors have approved the appointment of M/s P.S. Rao & Associates, Practising Company Secretaries (Firm Registration No. P2001TL078000), as the Secretarial Auditors of the Company, for a term of five consecutive financial years commencing from April 1, 2025 till March 31, 2030, subject to the approval of the shareholders at the ensuing AGM.

The details as required under Regulation 30 of the SEBI Listing Regulations, read with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, with respect to the above appointment is enclosed as **Annexure B**.

The meeting of Board of Directors of the Company commenced at 2:00 p.m. and concluded at 3.46 p.m.

The above information will also be available on the website of the Company at www.neulandlabs.com.

This is for your information and records.

Thanking you,

Yours Sincerely,

For Neuland Laboratories Limited


Sarada Bhamidipati
Company Secretary



Encl: As above

Independent Auditor's Report on Consolidated Audited Annual Financial Results of the Neuland Laboratories Limited pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, as amended.

**To the Board of Directors of Neuland Laboratories Limited
Report on the Audit of Consolidated Financial Results**

Opinion

We have audited the accompanying Statement of Consolidated annual financial results of **Neuland Laboratories Limited** ("the Holding Company") and its subsidiaries (Holding Company and its subsidiaries together referred to as "the Group"), for the year ended March 31, 2025 ("the Statement") attached herewith, being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us, and based on the consideration of reports of other auditors on separate audited financial statements of the subsidiaries, the aforesaid Statement:

- (i) includes the annual financial results of the Holding Company and the following entities:

| Sr. No | Name of the Entities | Relationship with the Holding Company |
|--------|----------------------------------|---------------------------------------|
| 1 | Neuland Laboratories K.K., Japan | Wholly Owned Subsidiary |
| 2 | Neuland Laboratories Inc., USA | Wholly Owned Subsidiary |

- (ii) is presented in accordance with the requirements of the Listing Regulations in this regard; and
- (iii) gives a true and fair view in conformity with the recognition and measurement principles laid down in the applicable accounting standards prescribed under Section 133 of the Companies Act, 2013 ("the Act"), read with Companies (Indian Accounting Standards) Rules, 2015, as amended, and other accounting principles generally accepted in India, of the net profit and total comprehensive income and other financial information of the Group, for the year ended March 31, 2025.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing ("SAs") specified under section 143(10) of the Act. Our responsibilities under those SAs are further described in the Auditor's Responsibilities for the Audit of the Consolidated Financial Results section of our report. We are independent of the Group in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the consolidated financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics.

We believe that the audit evidence obtained by us and other auditors in terms of their reports referred to in "Other Matters" paragraph below, is sufficient and appropriate to provide a basis for our opinion.

Management and Board of Directors' Responsibilities for the Consolidated Financial Results

This Statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors, has been prepared on the basis of the consolidated annual financial statements. The Holding Company's Board of Directors are responsible for the preparation and presentation of this Statement that gives a true and fair view of the net profit and total comprehensive income and other financial information of the Group in accordance with the recognition and measurement principles laid down in accordance with the Indian Accounting Standards prescribed under Section 133 of the Act read with Companies (Indian Accounting Standards) Rules, 2015, as amended and other accounting principles generally accepted in India and in compliance with the Listing Regulations. The respective Board of Directors of the companies included



in the Group are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Group and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the Statement by the Directors of the Holding Company, as aforesaid.

In preparing the Statement, the respective Board of Directors of the companies included in the Group are responsible for assessing the ability of the Group to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the respective Board of Directors either intends to liquidate the Group or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the companies included in the Group are responsible for overseeing the financial reporting process of the Group.

Auditor's Responsibilities for the Audit of the Consolidated Financial Results

Our objectives are to obtain reasonable assurance about whether the Statement as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this Statement.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3) (i) of the Act, we are also responsible for expressing our opinion on whether the Holding Company has adequate internal financial controls with reference to consolidated financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Group to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Statement or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Statement, including the disclosures, and whether the Statement represent the underlying transactions and events in a manner that achieves fair presentation.



- Obtain sufficient appropriate audit evidence regarding the financial information of the entities within the Group to express an opinion on the Statement. We are responsible for the direction, supervision and performance of the audit of financial information of such entities included in the Statement of which we are the independent auditors. For the other entities included in the Statement, which have been audited by other auditors, such other auditors remain responsible for the direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion.

We communicate with those charged with governance of the Holding Company regarding among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

We also performed procedures in accordance with the circular issued by SEBI under Regulation 33(8) of the Listing Regulations, to the extent applicable.

Other Matters

1. The Statement includes the audited financial results of two subsidiaries whose financial information reflect total assets of Rs. 1,056.79 lakhs as at March 31, 2025, total revenue of Rs. 1,929.44 lakhs, total net profit after tax of Rs. 68.27 lakhs, and total comprehensive income of Rs. 84.98 lakhs for the period from April 01, 2024 to March 31, 2025, and net cash inflow of Rs. 4.17 lakhs for the year ended as on date respectively, as considered in the Statement. These Financial Statements have been prepared in accordance with the accounting principles generally accepted in their respective countries and which have been audited by the other auditors under generally accepted auditing standards applicable in their respective countries. The Holding Company's Management has converted the financial statements of such subsidiaries located outside India from accounting principles generally accepted in their respective countries to accounting principles generally accepted in India. These conversion adjustments made by the Management of the Holding Company have not been audited by their auditors. Our opinion on the Statement, in so far as it relates to the financial information of such subsidiaries located outside India is based on the report of other auditor's and the conversion adjustments prepared by the Management of the Holding Company. In our opinion and according to the information and explanations given to us by the Management, these financial information are not material to the Group.
2. The Statement includes the results for the quarter ended March 31, 2025, being the balancing figure between the audited figures in respect of the full financial year ended March 31, 2025, and the published unaudited year to date figures up to the third quarter of the current financial year prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" which were subject to limited review by us.

Our opinion is not modified in respect of the above matters.

For M S K A & Associates
Chartered Accountants
ICAI Firm Registration No.105047W


Prakash Chandra Bhutada
Partner
Membership No.: 404621



UDIN: 25404621BMOTEP4279

Place: Hyderabad, India
Date: May 15, 2025

CONTACT
040 6761 1600 / 6761 1700
neuland@neulandlabs.com
neulandlabs.com

NEULAND LABORATORIES LIMITED
11th Floor (5th Office Level), Phoenix IVY Building, Plot No. 573A-III,
Road No 82, Jubilee Hills, Hyderabad - 500033
STATEMENT OF CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED MARCH 31, 2025

(Amount in lakhs of ₹, unless otherwise stated)

| Sl. No. | Particulars | Quarter Ended | | | Year Ended | |
|---------|--|------------------------------|---------------------------|------------------------------|-------------------------|-------------------------|
| | | 31.03.2025 (Refer Note 8) | 31.12.2024 (Unaudited) | 31.03.2024 (Refer Note 8) | 31.03.2025 (Audited) | 31.03.2024 (Audited) |
| 1 | Income | | | | | |
| | (a) Revenue from operations | 32,836.00 | 39,803.18 | 38,500.97 | 147,683.73 | 155,858.05 |
| | (b) Other income | 746.43 | 390.56 | 535.70 | 2,050.93 | 1,254.43 |
| | Total Income | 33,582.43 | 40,193.74 | 39,036.67 | 149,734.66 | 157,112.48 |
| 2 | Expenses | | | | | |
| | (a) Cost of materials consumed | 14,124.15 | 14,544.12 | 17,498.27 | 57,480.68 | 63,242.68 |
| | (b) Changes in inventories of finished goods and work-in-progress | (1,434.14) | 2,094.53 | (3,746.84) | 1,283.12 | (5,514.40) |
| | (c) Employee benefits expense | 6,645.75 | 6,934.12 | 6,248.88 | 27,200.48 | 25,706.27 |
| | (d) Finance costs | 234.67 | 221.67 | 360.90 | 829.71 | 1,399.74 |
| | (e) Depreciation and amortisation expenses | 1,689.19 | 1,630.03 | 1,646.26 | 6,554.66 | 5,969.99 |
| | (f) Manufacturing expenses | 4,509.03 | 3,933.80 | 4,250.56 | 16,287.00 | 15,651.39 |
| | (g) Other expenses | 3,883.82 | 3,636.78 | 3,558.44 | 13,106.47 | 10,513.16 |
| | Total expenses | 29,652.47 | 32,995.05 | 29,816.47 | 122,742.12 | 116,968.83 |
| 3 | Profit before exceptional items and tax (1-2) | 3,929.96 | 7,198.69 | 9,220.20 | 26,992.54 | 40,143.65 |
| 4 | Exceptional items (Refer Note 5) | - | 5,577.80 | - | 7,640.36 | - |
| 5 | Profit before tax (3+4) | 3,929.96 | 12,776.49 | 9,220.20 | 34,632.90 | 40,143.65 |
| 6 | Tax expense | | | | | |
| | (a) Current tax | 602.33 | 2,495.10 | 2,199.08 | 7,376.68 | 9,967.10 |
| | (b) Deferred tax | 547.04 | 122.71 | 264.93 | 1,245.41 | 168.66 |
| 7 | Profit for the period / year (5-6) | 2,780.59 | 10,158.68 | 6,756.19 | 26,010.81 | 30,007.89 |
| 8 | Other comprehensive income (net of taxes) | | | | | |
| | (a) Items not to be reclassified to profit or loss | | | | | |
| | Re-measurement gain/(loss) on defined benefit plans | (3.22) | - | 26.76 | (56.30) | 77.10 |
| | Equity instruments through other comprehensive income | 26.63 | - | 103.15 | 27.99 | 109.06 |
| | Tax on items that will not be reclassified to profit or loss | (5.90) | - | (32.70) | 7.12 | (45.37) |
| | (b) Items to be reclassified to profit or loss | | | | | |
| | Exchange differences in translating the financial statements of foreign operations | 2.85 | (0.25) | (8.38) | 16.71 | (4.86) |
| | Total comprehensive income | 2,800.95 | 10,158.43 | 6,845.02 | 26,006.33 | 30,143.82 |
| 9 | Paid-up Equity Share Capital (Face value - ₹10 each) | 1,290.05 | 1,290.05 | 1,290.05 | 1,290.05 | 1,290.05 |
| 10 | Other equity (excluding revaluation reserve) | - | - | - | 151,106.69 | 126,896.54 |
| 11 | Earnings Per Share (of ₹10 each) (In absolute ₹ terms) | | | | | |
| | (a) Basic (Refer Note 6) | 21.67 | 79.18 | 52.66 | 202.74 | 233.89 |
| | (b) Diluted (Refer Note 6) | 21.67 | 79.18 | 52.66 | 202.74 | 233.89 |
| | See accompanying notes to the financial results | | | | | |


NOTES:

- The financial results for the quarter and year ended March 31, 2025 have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on May 15, 2025.
- The financial results have been prepared in accordance with the Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations,
- The consolidated financial results include results of the following wholly owned subsidiaries:
(a) Neuland Laboratories Inc., USA
(b) Neuland Laboratories KK., Japan.
- The operations of the Company are predominantly related to the manufacture and sale of active pharmaceutical ingredients and allied services. As such there is only one primary reportable segment as per Ind AS 108 "Operating Segments".
- During the year, the Company has fully transferred an investment property located in Nanakramguda, Hyderabad, Telangana, through perpetual lease, resulting in total profit of ₹ 7,640.36 lakhs (For the quarter ended June 30, 2024: ₹ 2,062.56 lakhs and for the quarter ended December 31, 2024: ₹ 5,577.80 lakhs) being the profit is exceptional in nature, it has been disclosed as a separate line item.
- The EPS for quarters has not been annualised.
- The Board of Directors has recommended a dividend of ₹ 12/- (Rupee twelve) only per equity share of ₹ 10 each subject to approval of shareholders for the year ended March 31, 2025.
- Figures for the quarter ended March 31, 2025 and March 31, 2024 are the balancing figures between the audited figures in respect of the full financial year and the published unaudited figures upto nine months of the relevant financial year.

NEULAND LABORATORIES LIMITED
STATEMENT OF CONSOLIDATED ASSETS AND LIABILITIES AS AT MARCH 31, 2025

(Amount in lakhs of ₹, unless otherwise stated)

| Particulars | 31.03.2025 (Audited) | 31.03.2024 (Audited) |
|--|-------------------------|-------------------------|
| ASSETS | | |
| Non-current assets | | |
| Property, plant and equipment | 65,373.07 | 51,050.36 |
| Right-of-use assets | 1,998.28 | 1,221.75 |
| Capital work-in-progress | 4,455.29 | 4,589.13 |
| Investment property | - | 1,902.76 |
| Goodwill | 27,946.10 | 27,946.10 |
| Other intangible assets | 174.32 | 245.81 |
| Intangible assets under development | 311.08 | - |
| Financial assets | | |
| (i) Investments | 152.89 | 127.88 |
| (ii) Other financial assets | 935.16 | 846.71 |
| Income tax assets (net) | 1,132.33 | 1,035.69 |
| Other non-current assets | 1,559.95 | 2,181.84 |
| Total non-current assets | 104,038.47 | 91,148.03 |
| Current assets | | |
| Inventories | 38,575.69 | 35,042.19 |
| Financial assets | | |
| (i) Investments | 10,768.27 | - |
| (ii) Trade receivables | 31,572.06 | 37,352.62 |
| (iii) Cash and cash equivalents | 13,193.04 | 8,757.54 |
| (iv) Bank balances other than cash and cash equivalents | 12,688.86 | 2,922.00 |
| (v) Other financial assets | 221.56 | 288.79 |
| Other current assets | 6,930.21 | 7,744.93 |
| Total current assets | 113,949.69 | 92,108.07 |
| Total assets | 217,988.16 | 183,256.10 |
| EQUITY AND LIABILITIES | | |
| Equity | | |
| Equity share capital | 1,290.05 | 1,290.05 |
| Other equity | 151,190.58 | 126,980.43 |
| Total equity | 152,480.63 | 128,270.48 |
| Liabilities | | |
| Non-current liabilities | | |
| Financial liabilities | | |
| (i) Borrowings | 9,072.74 | 4,492.06 |
| (ia) Lease liabilities | 1,861.76 | 920.34 |
| Provisions | 722.23 | 760.98 |
| Deferred tax liabilities (net) | 7,282.21 | 6,043.92 |
| Total non-current liabilities | 18,938.94 | 12,217.30 |
| Current liabilities | | |
| Financial liabilities | | |
| (i) Borrowings | 4,528.27 | 3,758.64 |
| (ia) Lease liabilities | 250.99 | 367.92 |
| (ii) Trade payables | | |
| - total outstanding dues of micro and small enterprises | 843.04 | 974.41 |
| - total outstanding dues of creditors other than micro and small enterprises | 24,377.32 | 18,221.50 |
| (iii) Other financial liabilities | 8,454.70 | 10,660.45 |
| Provisions | 209.72 | 163.59 |
| Other current liabilities | 7,895.70 | 8,613.67 |
| Current tax liabilities (net) | 8.85 | 8.14 |
| Total current liabilities | 46,568.59 | 42,768.32 |
| Total liabilities | 65,507.53 | 54,985.62 |
| Total Equity and liabilities | 217,988.16 | 183,256.10 |



NEULAND LABORATORIES LIMITED
CONSOLIDATED STATEMENT OF CASH FLOWS

(Amount in lakhs of ₹, unless otherwise stated)

| Particulars | Year Ended | |
|--|-------------------------|-------------------------|
| | 31.03.2025 (Audited) | 31.03.2024 (Audited) |
| Cash flow from operating activities | | |
| Profit before tax | 34,632.90 | 40,143.65 |
| Adjustments to reconcile profit before tax to net cash flow: | | |
| Depreciation and amortisation expenses | 6,554.66 | 5,969.99 |
| Interest income | (1,058.40) | (822.68) |
| Loss on sale of property, plant and equipment, net | 731.06 | 40.16 |
| Gain on sale of investment properties (Exceptional items) | (7,640.36) | - |
| Finance costs | 829.71 | 1,399.74 |
| Provision towards/(write back) credit impaired trade receivables | 170.06 | (24.95) |
| Gain on fair valuation of investment carried at FVTPL | (768.27) | - |
| Unrealised foreign exchange gain, net | (18.95) | (354.71) |
| Operating cash flows before working capital changes | 33,432.41 | 46,351.20 |
| Movements in working capital: | | |
| Adjustments for (increase)/decrease in operating assets: | | |
| Inventories | (3,533.50) | (7,118.85) |
| Trade receivables | 5,490.67 | (866.29) |
| Other financial assets | 62.52 | 327.41 |
| Other assets | 838.04 | (2,242.24) |
| Adjustments for increase/(decrease) in operating liabilities: | | |
| Trade payables | 5,875.67 | 2,032.84 |
| Other financial liabilities | (2,285.13) | 4,194.90 |
| Provision for employee benefits | (48.92) | (199.49) |
| Other liabilities | (620.86) | (5,201.46) |
| Cash generated from operating activities | 39,210.90 | 37,278.02 |
| Income-taxes paid (net) | (7,472.62) | (11,160.35) |
| Net cash flow from operating activities (A) | 31,738.28 | 26,117.67 |
| Cash flows from investing activities | | |
| Purchase of property, plant and equipment and other intangible assets | (20,646.40) | (14,366.98) |
| Proceeds from sale of investments property | 9,543.13 | - |
| Proceeds from sale of property, plant and equipment | 116.42 | 126.32 |
| Purchase of short term investments | (10,000.00) | - |
| Proceeds from redemption/sale of non-current investments (net) | 2.97 | 33.67 |
| Movement in other bank balances (net) | (9,760.76) | (1,551.01) |
| Interest income received | 929.05 | 789.32 |
| Net cash used in investing activities (B) | (29,815.59) | (14,968.68) |
| Cash flows from financing activities | | |
| Proceeds from long-term borrowings | 9,477.82 | 882.19 |
| Repayment of long-term borrowings | (3,943.53) | (3,710.46) |
| Repayment of short-term borrowings (net) | - | (1,115.75) |
| Finance cost paid | (700.28) | (1,338.20) |
| Dividend paid | (1,796.18) | (1,282.99) |
| Payment of lease liabilities | (404.05) | (295.68) |
| Interest on lease liabilities | (137.68) | (67.29) |
| Net cash flow from/(used) in financing activities (C) | 2,496.10 | (6,928.18) |
| Net increase in cash and cash equivalents during the year (A + B + C) | 4,418.79 | 4,220.81 |
| Cash and cash equivalents at the beginning of the year | 8,757.54 | 4,541.59 |
| Effects of exchange rate changes on cash and cash equivalents | 16.71 | (4.86) |
| Cash and cash equivalents at the end of the year | 13,193.04 | 8,757.54 |

Place: Hyderabad
Date: May 15, 2025



For Neuland Laboratories Limited


Dr. D R Rao
Executive Chairman
(DIN 00107737)



Independent Auditor's Report on Standalone Audited Annual Financial Results of the Neuland Laboratories Limited pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, as amended.

**To the Board of Directors of Neuland Laboratories Limited
Report on the Audit of Standalone Financial Results**

Opinion

We have audited the accompanying statement of standalone annual financial results of Neuland Laboratories Limited ("the Company") for the year ended March 31, 2025 ("the Statement"), attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid Statement:

- (i) is presented in accordance with the requirements of the Listing Regulations in this regard; and
- (ii) gives a true and fair view, in conformity with the recognition and measurement principles laid down in the applicable accounting standards prescribed under Section 133 of the Companies Act, 2013 ("the Act"), read with Companies (Indian Accounting Standards) Rules, 2015, as amended, and other accounting principles generally accepted in India, of the net profit and total comprehensive income and other financial information of the Company for the year ended March 31, 2025.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing ("SAs") specified under section 143(10) of the Act. Our responsibilities under those SAs are further described in the Auditor's Responsibilities for the Audit of the Standalone financial results section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the standalone financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics.

We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our opinion.

Management and Board of Directors' Responsibilities for the Standalone Annual Financial Results

This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared on the basis of the standalone annual financial statements. The Company's Board of Directors are responsible for the preparation and presentation of this Statement that gives a true and fair view of the net profit and total comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in accordance with the Indian Accounting Standards prescribed under Section 133 of the Act read with Companies (Indian Accounting Standards) Rules, 2015, as amended, issued thereunder and other accounting principles generally accepted in India and is in compliance with the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act, for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that give a true and fair view and are free from material misstatement, whether due to fraud or error.



In preparing the Statement, the Board of Directors of the Company are responsible for assessing the ability of the Company to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are responsible for overseeing the financial reporting process of the Company.

Auditor's Responsibilities for the Audit of the Standalone Financial Results

Our objectives are to obtain reasonable assurance about whether the Statement as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these Statement.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3) (i) of the Act, we are also responsible for expressing our opinion on whether the Company has adequate internal financial controls with reference to standalone financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Company to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Statement or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Statement, including the disclosures, and whether the Statement represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance of the Company regarding among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.



MSKA & Associates

Chartered Accountants

Other Matter

The Statement includes the results for the quarter ended March 31, 2025 being the balancing figure between the audited figures in respect of the full financial year and the published unaudited year to date figures up to the third quarter of the current financial year prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" which were subject to limited review by us.

Our opinion on the Statement is not modified in respect of the above matter.

For M S K A & Associates

Chartered Accountants

ICAI Firm Registration No.105047W



Prakash Chandra Bhutada

Partner

Membership No. 404621



UDIN: 25404621BMOTER8066

Place: Hyderabad, India

Date: May 15, 2025

CONTACT
040 6761 1600 / 6761 1700
neuland@neulandlabs.com
neulandlabs.com


NEULAND LABORATORIES LIMITED
11th Floor (5th Office Level), Phoenix IVY Building, Plot No. 573A-III,
Road No 82, Jubilee Hills, Hyderabad - 500033
STATEMENT OF STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED MARCH 31, 2025

(Amount in lakhs of ₹, unless otherwise stated)

| Sl. No. | Particulars | Quarter Ended | | | Year Ended | |
|---------|---|------------------------------|---------------------------|------------------------------|-------------------------|-------------------------|
| | | 31.03.2025 (Refer Note 7) | 31.12.2024 (Unaudited) | 31.03.2024 (Refer Note 7) | 31.03.2025 (Audited) | 31.03.2024 (Audited) |
| 1 | Income | | | | | |
| | (a) Revenue from operations | 32,836.00 | 39,803.18 | 38,500.97 | 147,683.73 | 155,858.05 |
| | (b) Other income | 746.38 | 390.55 | 535.70 | 2,050.86 | 1,254.43 |
| | Total Income | 33,582.38 | 40,193.73 | 39,036.67 | 149,734.59 | 157,112.48 |
| 2 | Expenses | | | | | |
| | (a) Cost of materials consumed | 14,124.15 | 14,544.12 | 17,498.27 | 57,480.68 | 63,242.68 |
| | (b) Changes in inventories of finished goods and work-in-progress | (1,434.14) | 2,094.53 | (3,746.84) | 1,283.12 | (5,514.40) |
| | (c) Employee benefits expense | 6,419.13 | 6,721.05 | 6,100.99 | 26,139.85 | 24,853.48 |
| | (d) Finance costs | 234.60 | 221.64 | 360.90 | 829.59 | 1,399.72 |
| | (e) Depreciation and amortisation expenses | 1,689.04 | 1,629.93 | 1,646.18 | 6,554.19 | 5,969.91 |
| | (f) Manufacturing expenses | 4,509.03 | 3,933.80 | 4,250.56 | 16,287.00 | 15,651.39 |
| | (g) Other expenses | 4,142.39 | 3,872.00 | 3,718.52 | 14,263.19 | 11,432.78 |
| | Total expenses | 29,684.20 | 33,017.07 | 29,828.58 | 122,837.62 | 117,035.56 |
| 3 | Profit before exceptional items and tax (1-2) | 3,898.18 | 7,176.66 | 9,208.09 | 26,896.97 | 40,076.92 |
| 4 | Exceptional items (Refer Note 4) | - | 5,577.80 | - | 7,640.36 | - |
| 5 | Profit before tax (3+4) | 3,898.18 | 12,754.46 | 9,208.09 | 34,537.33 | 40,076.92 |
| 6 | Tax expense | | | | | |
| | (a) Current tax | 593.67 | 2,492.38 | 2,192.37 | 7,365.30 | 9,958.57 |
| | (b) Deferred tax | 531.12 | 122.71 | 255.00 | 1,229.49 | 158.73 |
| 7 | Profit for the period / year (5-6) | 2,773.39 | 10,139.37 | 6,760.72 | 25,942.54 | 29,959.62 |
| 8 | Other comprehensive income (net of taxes) | | | | | |
| | Items not to be reclassified to profit or loss | | | | | |
| | Re-measurement gain/(loss) on defined benefit plans | (3.22) | - | 26.76 | (56.30) | 77.10 |
| | Equity instruments through other comprehensive income | 26.63 | - | 103.15 | 27.99 | 109.06 |
| | Tax on items that will not be reclassified to profit or loss | (5.90) | - | (32.70) | 7.12 | (45.37) |
| | Total comprehensive income | 2,790.90 | 10,139.37 | 6,857.93 | 25,921.35 | 30,100.41 |
| 9 | Paid-up Equity Share Capital (Face value - ₹10 each) | 1,290.05 | 1,290.05 | 1,290.05 | 1,290.05 | 1,290.05 |
| 10 | Other equity (excluding revaluation reserve) | - | - | - | 150,405.12 | 126,279.95 |
| 11 | Earnings Per Share (of ₹10 each) (In absolute ₹ terms) | | | | | |
| | (a) Basic (Refer Note 5) | 21.62 | 79.03 | 52.70 | 202.20 | 233.51 |
| | (b) Diluted (Refer Note 5) | 21.62 | 79.03 | 52.70 | 202.20 | 233.51 |
| | See accompanying notes to the financial results | | | | | |

NOTES:


- The financial results for the quarter and year ended March 31, 2025 have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on May 15, 2025.
- The financial results have been prepared in accordance with the Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations,
- The operations of the Company are predominantly related to the manufacture and sale of active pharmaceutical ingredients and allied services. As such there is only one primary reportable segment as per Ind AS 108 "Operating Segments".
- During the year, the Company has fully transferred an investment property located in Nanakramguda, Hyderabad, Telangana, through perpetual lease, resulting in total profit of ₹ 7,640.36 lakhs (For the quarter ended June 30, 2024: ₹ 2,062.56 lakhs and for the quarter ended December 31, 2024: ₹ 5,577.80 lakhs) being the profit is exceptional in nature, it has been disclosed as a separate line item.
- The EPS for quarters has not been annualised.
- The Board of Directors has recommended a final dividend of ₹ 12/- (Rupees twelve) only per equity share of ₹ 10 each subject to approval of shareholders for the year ended March 31, 2025.
- The figures for the quarter ended March 31, 2025 and March 31, 2024 are the balancing figures between the audited figures in respect of the full financial year and the published unaudited figures upto nine months of the relevant financial year.



NEULAND LABORATORIES LIMITED
STATEMENT OF STANDALONE ASSETS AND LIABILITIES AS AT MARCH 31, 2025

(Amount in lakhs of ₹, unless otherwise stated)

| Particulars | 31.03.2025 (Audited) | 31.03.2024 (Audited) |
|--|-------------------------|-------------------------|
| ASSETS | | |
| Non-current assets | | |
| Property, plant and equipment | 65,370.33 | 51,048.96 |
| Right-of-use assets | 1,998.28 | 1,221.75 |
| Capital work-in-progress | 4,455.29 | 4,589.13 |
| Investment property | - | 1,902.76 |
| Goodwill | 27,946.10 | 27,946.10 |
| Other intangible assets | 174.32 | 245.81 |
| Intangible assets under development | 311.08 | - |
| Financial assets | | |
| (i) Investments | 168.71 | 143.70 |
| (ii) Other financial assets | 919.05 | 831.06 |
| Income tax assets (net) | 1,132.33 | 1,035.69 |
| Other non-current assets | 1,559.81 | 2,180.93 |
| Total non-current assets | 104,035.30 | 91,145.89 |
| Current assets | | |
| Inventories | 38,575.69 | 35,042.19 |
| Financial assets | | |
| (i) Investments | 10,768.27 | - |
| (ii) Trade receivables | 31,572.06 | 37,352.62 |
| (iii) Cash and cash equivalents | 13,037.90 | 8,606.57 |
| (iv) Bank balances other than cash and cash equivalents | 12,688.86 | 2,922.00 |
| (v) Other financial assets | 221.56 | 288.79 |
| Other current assets | 6,917.40 | 7,734.66 |
| Total current assets | 113,781.74 | 91,946.83 |
| Total assets | 217,817.04 | 183,092.72 |
| EQUITY AND LIABILITIES | | |
| Equity | | |
| Equity share capital | 1,290.05 | 1,290.05 |
| Other equity | 150,489.01 | 126,363.84 |
| Total equity | 151,779.06 | 127,653.89 |
| Liabilities | | |
| Non-current liabilities | | |
| Financial liabilities | | |
| (i) Borrowings | 9,072.74 | 4,492.06 |
| (ii) Lease liabilities | 1,861.76 | 920.34 |
| Provisions | 663.74 | 712.76 |
| Deferred tax liabilities (net) | 7,156.07 | 5,933.70 |
| Total non-current liabilities | 18,754.31 | 12,058.86 |
| Current liabilities | | |
| Financial liabilities | | |
| (i) Borrowings | 4,528.27 | 3,758.64 |
| (ii) Lease liabilities | 250.99 | 367.92 |
| (iii) Trade payables | | |
| - total outstanding dues of micro and small enterprises | 843.04 | 974.41 |
| - total outstanding dues of creditors other than micro and small enterprises | 25,247.16 | 18,879.47 |
| (iii) Other financial liabilities | 8,321.71 | 10,632.77 |
| Provisions | 209.72 | 163.59 |
| Other current liabilities | 7,882.78 | 8,603.17 |
| Total current liabilities | 47,283.67 | 43,379.97 |
| Total liabilities | 66,037.98 | 55,438.83 |
| Total equity and liabilities | 217,817.04 | 183,092.72 |



NEULAND LABORATORIES LIMITED
STANDALONE STATEMENT OF CASH FLOWS

(Amount in lakhs of ₹, unless otherwise stated)

| Particulars | Year Ended | |
|--|-------------------------|-------------------------|
| | 31.03.2025 (Audited) | 31.03.2024 (Audited) |
| Cash flow from operating activities | | |
| Profit before tax | 34,537.33 | 40,076.92 |
| Adjustments to reconcile profit before tax to net cash flow: | | |
| Depreciation and amortisation expenses | 6,554.19 | 5,969.91 |
| Interest income | (1,058.33) | (822.68) |
| Loss on sale of property, plant and equipment, net | 731.06 | 40.16 |
| Gain on sale of investment properties (Exceptional items) | (7,640.36) | - |
| Finance costs | 829.59 | 1,399.72 |
| Provision towards/(write back) credit impaired trade receivables | 170.06 | (24.95) |
| Gain on fair valuation of investments carried at FVTPL | (768.27) | - |
| Unrealised foreign exchange gain, net | (18.95) | (354.71) |
| Operating cash flows before working capital changes | 33,336.32 | 46,284.37 |
| Movements in working capital: | | |
| Adjustments for (increase)/decrease in operating assets: | | |
| Inventories | (3,533.50) | (7,118.85) |
| Trade receivables | 5,490.67 | (866.29) |
| Other financial assets | 62.98 | 325.48 |
| Other assets | 839.80 | (2,226.18) |
| Adjustments for increase/(decrease) in operating liabilities: | | |
| Trade payables | 6,087.54 | 1,992.08 |
| Other financial liabilities | (2,390.44) | 4,174.75 |
| Provision for employee benefits | (59.19) | (201.94) |
| Other liabilities | (623.29) | (5,200.68) |
| Cash generated from operating activities | 39,210.89 | 37,162.74 |
| Income-taxes paid (net) | (7,461.94) | (11,156.54) |
| Net cash flow from operating activities (A) | 31,748.95 | 26,006.20 |
| Cash flows from investing activities | | |
| Purchase of property, plant and equipment and other intangible assets | (20,644.58) | (14,365.50) |
| Proceeds from sale of investments property | 9,543.13 | - |
| Proceeds from sale of property, plant and equipment | 116.42 | 126.32 |
| Purchase of short term investments | (10,000.00) | - |
| Proceeds from redemption/sale of non-current investments (net) | 2.97 | 33.67 |
| Movement in other bank balances (net) | (9,760.76) | (1,551.01) |
| Interest income received | 928.98 | 789.32 |
| Net cash used in investing activities (B) | (29,813.84) | (14,967.20) |
| Cash flows from financing activities | | |
| Proceeds from long-term borrowings | 9,477.82 | 882.19 |
| Repayment of long-term borrowings | (3,943.53) | (3,710.46) |
| Repayment of short-term borrowings (net) | - | (1,115.75) |
| Finance cost paid | (700.16) | (1,338.19) |
| Dividend paid | (1,796.18) | (1,282.99) |
| Payment of lease liabilities | (404.05) | (295.68) |
| Interest on lease liabilities | (137.68) | (67.29) |
| Net cash flow from/(used) in financing activities (C) | 2,496.22 | (6,928.17) |
| Net increase in cash and cash equivalents during the year (A + B + C) | 4,431.33 | 4,110.83 |
| Cash and cash equivalents at the beginning of the year | 8,606.57 | 4,495.74 |
| Cash and cash equivalents at the end of the year | 13,037.90 | 8,606.57 |

For Neuland Laboratories Limited



Dr. D R Rao
Executive Chairman
(DIN 00107737)



Place: Hyderabad
Date: May 15, 2025



Annexure A

Details required under Regulation 30 of SEBI Regulations read with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024

Details of Mr. Davuluri Saharsh Rao

| Sl. No. | Particulars | Remarks |
|---------|--|--|
| 1. | DIN | 02753145 |
| 2. | Reason for change viz. appointment, resignation, removal, death or otherwise | Re-appointment |
| 3. | Date of appointment and term of appointment | Re-appointment as Whole Time Director of the Company designated as Vice Chairman & Managing Director, for a further period of 5 (five) years, w.e.f. June 1, 2025, subject to the approval of the shareholders of the Company in the ensuing Annual General Meeting. |
| 4. | Brief Profile | <p>Mr. Davuluri Saharsh Rao joined the Company in March 2005 as Chief Information Officer, later taking charge of the Custom Manufacturing Solutions (CMS) business. Appointed as a Whole Time Director in 2009, he was re-appointed at the 36th Annual General Meeting on July 10, 2020, for a five-year term ending May 31, 2025. Mr. Saharsh has driven business development for CMS, overseeing Marketing, R&D, Project Management, IT, and Investor Relations. He has focused on enhancing Neuland's capabilities in Research & Development, particularly in Peptides, strengthening the organization with skills like Project Management and Digital Marketing. Alongside the CEO, he formulates and executes long-term strategic plans.</p> <p>He holds a Bachelor's in Electrical Engineering, a Master's in Management Information Systems from Weatherhead School of Management, Cleveland, Ohio, and an MBA from the University of North Carolina, USA. His career includes roles in Sales at Sify Limited and involvement with a lifesciences-focused venture fund in the Research Triangle.</p> |
| 5. | Disclosure of relationships between directors | Mr. D. Saharsh Rao is the son of Dr. D. Rama Mohan Rao, Executive Chairman, and brother of Mr. D. Sucheth Rao, Vice Chairman and CEO, of the Company. |
| 6. | Information as required pursuant to BSE Circular with ref. no. LIST/COMP/ 14/ 2018-19 and the National Stock Exchange of India Ltd with ref. no. NSE/ CML/ 2018/24, dated 20th June 2018 | Mr. Davuluri Saharsh Rao is not debarred from holding the office of director by virtue of any SEBI order or any other such authority. |



Annexure B

Details required under Regulation 30 of SEBI Regulations read with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024

Appointment of M/s P.S. Rao & Associates, as the Secretarial Auditors of the Company

| Sl. No. | Particulars | Remarks |
|---------|--|--|
| 2. | Reason for change viz. appointment, resignation, removal, death or otherwise | Appointment |
| 3. | Date of appointment and term of appointment | Appointment of M/s P.S. Rao & Associates, Practising Company Secretaries (Firm Registration No. P2001TL078000), as the Secretarial Auditors of the Company, for a term of five consecutive financial years commencing from April 1, 2025 till March 31, 2030, subject to the approval of the shareholders at the ensuing AGM. |
| 4. | Brief Profile | M/s P. S. Rao & Associates, Practicing Company Secretaries is a firm established in the year 1994 by Mr. P S Rao, the Founder Partner. The firm, since then, is actively engaged in rendering Secretarial, Legal and other consultancy services to various Corporates across the globe. Over a period of 30 years, with an in – house strength of more than 80 professionals, both qualified as well as semi qualified, the firm has developed an adequate experience and expertise in dealing with various Corporate Law matters. |
| 5. | Disclosure of relationships between directors | Not Applicable |

